Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Hardy, S. Thompson (1998)
Detecting and describing heterogeneity in meta-analysis.Statistics in medicine, 17 8
E. Steyerberg, M. Eijkemans, J. Habbema (1999)
Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis.Journal of clinical epidemiology, 52 10
M. Egger, G. Smith (1995)
Misleading meta-analysisBMJ, 310
(2003)
Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs).
Cochrane Injuries, I. Roberts (1998)
Human albumin administration in critically ill patients: systematic review of randomised controlled trials.BMJ, 317
J. Sterne, M. Egger (2001)
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.Journal of clinical epidemiology, 54 10
R. Harbour, Julie Miller (2001)
A new system for grading recommendations in evidence based guidelinesBMJ : British Medical Journal, 323
(2001)
Which guidelines can we trust ?
A. Berger (1998)
Cochrane Injuries Group Albumin ReviewersWhy albumin may not workBMJ, 317
A. Howell (1998)
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.Lancet, 351 9114
J. Higgins, S. Thompson (2002)
Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 21
Joseph Lau, E. Antman, Jeanette Jimenez-Silva, B. Kupelnick, F. Mosteller, T. Chalmers (1992)
Cumulative meta-analysis of therapeutic trials for myocardial infarction.The New England journal of medicine, 327 4
R. Graves (2002)
Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice.Journal of The Medical Library Association, 90
M. Egger, G. Smith, D. Altman (2001)
Systematic reviews in health care : meta-analysis in context
T. Cleophas (1991)
The performance of the two-stage analysis of two-treatment, two-period crossover trials.Statistics in medicine, 10 3
D. Petitti (2001)
Approaches to heterogeneity in meta‐analysisStatistics in Medicine, 20
A. Liberati, R. Buzzetti, R. Grilli, N. Magrini, S. Minozzi (2001)
Evidence-Based Case Review: Which guidelines can we trust?: Assessing strength of evidence behind recommendations for clinical practiceWestern Journal of Medicine, 174
E. Engels, C. Schmid, N. Terrin, I. Olkin, Joseph Lau (2000)
Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses.Statistics in medicine, 19 13
(2002)
Treatment discontinuation with selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants (TCAs) Quantifying heterogeneity in a metaanalysis
T. Jefferson, Demicheli, J. Deeks, D. Rivetti (2004)
Amantadine and rimantadine for preventing and treating influenza A in adults.The Cochrane database of systematic reviews, 2
W. Cochran (1954)
The combination of estimates from different experiments.Biometrics, 10
(1998)
Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 351
A. Censo, D. Ciliska, M. Dobbins, G. Guyatt, M. Newman (2005)
Moving from evidence to action
K. Dickersin, J. Berlin (1992)
Meta-analysis: state-of-the-science.Epidemiologic reviews, 14
M. Egger, G. Smith (1997)
Meta-analysis: Potentials and promiseBMJ, 315
J. Deeks (2002)
Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomesStatistics in Medicine, 21
I. Angelillo, Paolo Villari (1999)
Residential exposure to electromagnetic fields and childhood leukaemia: a meta-analysis.Bulletin of the World Health Organization, 77 11
Sudhir Paul, Allan Donner (1992)
Small sample performance of tests of homogeneity of odds ratios in K 2 x 2 tables.Statistics in medicine, 11 2
J. Higgins, S. Thompson, J. Deeks, D. Altman (2002)
Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practiceJournal of Health Services Research and Policy, 7
(2001)
Meta-analysisinSTATA
Education and debate JulianPTHiggins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman Cochrane Reviews have recently started including the quantity I to help readers assess the consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is assessment of heterogeneity so important to clinical practice? MRC Biostatistics Systematic reviews and meta-analyses can provide intervals not overlapping. But the test of heterogeneity Unit, Institute of convincing and reliable evidence relevant to many yieldsaPvalue of 0.09, conventionally interpreted as Public Health, aspects of medicine and health care. Their value is being non-significant. Because the test is poor at Cambridge CB2 2SR especially clear when the results of the studies they detecting true heterogeneity, a non-significant result JulianPTHiggins include show clinically important effects of similar cannot be taken as evidence of homogeneity. Using a statistician magnitude. However, the conclusions are less clear cut-off of 10% for significance ameliorates this prob- Simon G when the included studies have differing results. In an Thompson lem but increases the risk of drawing a false positive director attempt to establish whether studies are consistent, 10 conclusion (type I error). reports of meta-analyses commonly present a statisti- Cancer Research Conversely,
BMJ – British Medical Journal
Published: Sep 6, 2003
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.